Academic challenges on advanced therapy medicinal products’ development: a regulatory perspective
- 23 January 2024
- journal article
- review article
- Published by Elsevier in Cytotherapy
- Vol. 26 (3) , 221-230
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial ApplicationsClinical and Translational Science, 2019
- Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplarCytotherapy, 2018
- Challenges of Running a GMP Facility for Regenerative Medicine in a Public HospitalRegenerative Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment conceptsEMBO Molecular Medicine, 2017
- Development of cell therapy medicinal products by academic institutesDrug Discovery Today, 2016
- Impact of scientific advice from the European Medicines AgencyNature Reviews Drug Discovery, 2015
- Regulation of advanced therapy medicinal products in Europe and the role of academiaCytotherapy, 2014
- The Evolution of Nonclinical Regulatory Science: Advanced Therapy Medicinal Products as a ParadigmMolecular Therapy, 2013
- NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cellsBlood, 2002